Skip to main content
Top
Gepubliceerd in: Quality of Life Research 7/2016

01-07-2016

Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology

Auteurs: Momar Diouf, Thomas Filleron, Anne-Laure Pointet, Anne-Claire Dupont-Gossard, David Malka, Pascal Artru, Mélanie Gauthier, Thierry Lecomte, Thomas Aparicio, Anne Thirot-Bidault, Céline Lobry, Francine Fein, Olivier Dubreuil, Bruno Landi, Aziz Zaanan, Julien Taieb, Franck Bonnetain

Gepubliceerd in: Quality of Life Research | Uitgave 7/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Eastern Cooperative Oncology Group Performance Status (ECOG-PS) is currently an important parameter in the choice of treatment strategy for metastatic pancreatic adenocarcinoma (mPA) patients. However, previous research has shown that patients’ self-reported health-related quality of life (HRQOL) scales provided additional prognostic information in homogeneous groups of patients with respect to ECOG-PS. The aim of this study was to identify HRQOL scales with independent prognostic value in mPA and to propose prognostic groups for these patients.

Methods

We analysed data from 98 chemotherapy-naive patients with histologically proven mPA recruited from 2007 to 2011 in the FIRGEM phase II study which aimed to compare the effectiveness of two chemotherapy regimen. HRQOL data were assessed with the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire. A random survival forest methodology was used to impute missing data and to identify major prognostic factors for overall survival.

Results

Baseline HRQOL assessment was completed by 60 % of patients (59/98). Twelve prognostic variables were identified. The three most important prognostic variables were fatigue, appetite loss, and role functioning, followed by three laboratory variables. The model’s discriminative power assessed by Harrell’s C statistic was 0.65. Fatigue score explained almost all the survival variability.

Conclusion

HRQOL scores have prognostic value for mPA patients with good ECOG-PS. Moreover, the patient’s fatigue, appetite loss, and self-perception of daily activities were more reliable prognostic indicators than clinical and laboratory variables. These HRQOL scores, especially the fatigue symptom, should be urgently included for prognostic assessment of mPA patients (with good ECOG-PS).
Literatuur
1.
go back to reference Ferlay, J., Soerjomataram, I., Dikshit, R., et al. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386.CrossRefPubMed Ferlay, J., Soerjomataram, I., Dikshit, R., et al. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386.CrossRefPubMed
3.
go back to reference International Union against Cancer. (2010). TNM classification of malignant tumours (7th ed.). Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell. International Union against Cancer. (2010). TNM classification of malignant tumours (7th ed.). Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell.
4.
go back to reference Seufferlein, T., Bachet, J. B., Van Cutsem, E., et al. (2012). Pancreatic adenocarcinoma: ESMO–ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(Suppl 7), vii33–vii40. doi:10.1093/annonc/mds224.CrossRefPubMed Seufferlein, T., Bachet, J. B., Van Cutsem, E., et al. (2012). Pancreatic adenocarcinoma: ESMO–ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(Suppl 7), vii33–vii40. doi:10.​1093/​annonc/​mds224.CrossRefPubMed
6.
go back to reference Bernhard, J., Dietrich, D., Glimelius, B., et al. (2010). Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. British Journal of Cancer, 103, 1318–1324. doi:10.1038/sj.bjc.6605929.CrossRefPubMedPubMedCentral Bernhard, J., Dietrich, D., Glimelius, B., et al. (2010). Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. British Journal of Cancer, 103, 1318–1324. doi:10.​1038/​sj.​bjc.​6605929.CrossRefPubMedPubMedCentral
7.
go back to reference Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., et al. (2013). Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. Journal of Clinical Oncology, 2013(31), 23–29. doi:10.1200/JCO.2012.44.4869.CrossRef Gourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., et al. (2013). Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. Journal of Clinical Oncology, 2013(31), 23–29. doi:10.​1200/​JCO.​2012.​44.​4869.CrossRef
9.
go back to reference Steyerberg, E. W. (2008). Clinical prediction models: A practical approach to development, validation, and updating (1st ed.). New York, NY: Springer-Verlag New York Inc. Steyerberg, E. W. (2008). Clinical prediction models: A practical approach to development, validation, and updating (1st ed.). New York, NY: Springer-Verlag New York Inc.
10.
go back to reference Trouilloud, I., Dupont-Gossard, A.-C., Malka, D., et al. (2014). Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM). European Journal of Cancer, 50, 3116–3124. doi:10.1016/j.ejca.2014.09.015.CrossRefPubMed Trouilloud, I., Dupont-Gossard, A.-C., Malka, D., et al. (2014). Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM). European Journal of Cancer, 50, 3116–3124. doi:10.​1016/​j.​ejca.​2014.​09.​015.CrossRefPubMed
12.
go back to reference Bonnetain, F., Bonsing, B., Conroy, T., et al. (2014). Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). European Journal of Cancer, 50, 2983–2993. doi:10.1016/j.ejca.2014.07.011.CrossRefPubMed Bonnetain, F., Bonsing, B., Conroy, T., et al. (2014). Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). European Journal of Cancer, 50, 2983–2993. doi:10.​1016/​j.​ejca.​2014.​07.​011.CrossRefPubMed
14.
go back to reference Van Steen, K., Curran, D., Kramer, J., et al. (2002). Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: Identification and impact on model selection. Statistics in Medicine, 21, 3865–3884. doi:10.1002/sim.1358.CrossRefPubMed Van Steen, K., Curran, D., Kramer, J., et al. (2002). Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: Identification and impact on model selection. Statistics in Medicine, 21, 3865–3884. doi:10.​1002/​sim.​1358.CrossRefPubMed
18.
21.
go back to reference Diouf, M., Bonnetain, F., Barbare, J.-C., et al. (2015). Optimal Cut Points for Quality of Life Questionnaire-Core 30 (QLQ-C30) Scales: Utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. The Oncologist, 20(1), 62–71.CrossRefPubMedPubMedCentral Diouf, M., Bonnetain, F., Barbare, J.-C., et al. (2015). Optimal Cut Points for Quality of Life Questionnaire-Core 30 (QLQ-C30) Scales: Utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. The Oncologist, 20(1), 62–71.CrossRefPubMedPubMedCentral
23.
go back to reference Haas, M., Heinemann, V., Kullmann, F., et al. (2013). Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: Results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. Journal of Cancer Research and Clinical Oncology, 139, 681–689. doi:10.1007/s00432-012-1371-3.CrossRefPubMed Haas, M., Heinemann, V., Kullmann, F., et al. (2013). Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: Results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. Journal of Cancer Research and Clinical Oncology, 139, 681–689. doi:10.​1007/​s00432-012-1371-3.CrossRefPubMed
24.
go back to reference Robinson, D. W., Eisenberg, D. F., Cella, D., et al. (2008). The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. The Journal of Supportive Oncology, 6, 283–290.PubMed Robinson, D. W., Eisenberg, D. F., Cella, D., et al. (2008). The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. The Journal of Supportive Oncology, 6, 283–290.PubMed
26.
go back to reference Mauer, M., Bottomley, A., Coens, C., et al. (2008). Prognostic factor analysis of health-related quality of life data in cancer: A statistical methodological evaluation. Expert Review of Pharmacoeconomics & Outcomes Research, 8, 179–196. doi:10.1586/14737167.8.2.179.CrossRef Mauer, M., Bottomley, A., Coens, C., et al. (2008). Prognostic factor analysis of health-related quality of life data in cancer: A statistical methodological evaluation. Expert Review of Pharmacoeconomics & Outcomes Research, 8, 179–196. doi:10.​1586/​14737167.​8.​2.​179.CrossRef
Metagegevens
Titel
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology
Auteurs
Momar Diouf
Thomas Filleron
Anne-Laure Pointet
Anne-Claire Dupont-Gossard
David Malka
Pascal Artru
Mélanie Gauthier
Thierry Lecomte
Thomas Aparicio
Anne Thirot-Bidault
Céline Lobry
Francine Fein
Olivier Dubreuil
Bruno Landi
Aziz Zaanan
Julien Taieb
Franck Bonnetain
Publicatiedatum
01-07-2016
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 7/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-1198-x

Andere artikelen Uitgave 7/2016

Quality of Life Research 7/2016 Naar de uitgave